CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders

Core Insights - CytoMed Therapeutics Limited is focusing on the development of affordable GMP-grade immune cells for patients with cancer and autoimmune diseases, leveraging Asia's low-cost infrastructure and talent [3][4] - The company has achieved significant milestones in 2024, including becoming a clinical stage biopharma and initiating the ANGELICA trial, which is the first-in-human CAR T trial using donor-derived allogeneic gamma delta T cells [4][10] - CytoMed has made strategic acquisitions and partnerships to expand its capabilities and market reach, including the acquisition of a licensed cord blood bank and collaborations in China and India [5][6] Company Developments - The ANGELICA trial commenced in November 2024, with a focus on late-stage cancer patients, supported by a grant from the National Medical Research Council of Singapore [4] - The acquisition of a cord blood bank for approximately US$ 450,000 aims to facilitate the development of cord blood-derived therapeutics, particularly for autoimmune diseases [5] - The company is establishing a presence in New York to enhance its profile in the US market and explore opportunities for mergers and acquisitions [10] Strategic Direction - CytoMed plans to implement revenue-generating methods for late-stage patients, including partnerships with clinics and hospitals in Asia [11] - The company is working towards submitting a US FDA IND for its allogeneic gamma delta T cells and aims for initial clinical readouts from the ANGELICA trial by mid-2025 [10] - The focus on international medical tourism in Asia presents opportunities for developing cell therapies that are often expensive or inaccessible in Western markets [11]